Health-related quality of life among patients with metastatic prostate cancer

Urology

Volumn 49, Issue 2, 1997, Pages 207-217

  Albertsen, Peter C ^a   Aaronson, Neil K ^b   Muller, Martin J ^b   Keller, Susan D ^b   Ware Jr , John E ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; GONADORELIN AGONIST;

AGED; ANALGESIA; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; METASTASIS; MULTICENTER STUDY; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SOCIAL INTERACTION;

ADENOCARCINOMA; AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FLUTAMIDE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; REMISSION INDUCTION;

EID: 0031036419     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00485-2     Document Type: Article

References (20)

1. Fossa SD, Kaasa S, da Silva FC, Suciu S, and Hengeveld MW: Quality of life in prostate cancer patients. Prostate 4(suppl): 145-148, 1992.
2. Litwin MS: Measuring health related quality of life in men with prostate cancer. J Urol 152: 1882-1887, 1994.
3. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach G, and Brooks RH: Quality of life outcomes in men treated for localized prostate cancer. JAMA 273: 129-135, 1995.
4. Pedersen KV, Carlsson P, Rahmquist M, and Varenhorst E: Quality of life after radical retropubic prostatectomy for carcinoma of the prostate. Eur Urol 24: 7-11, 1993.
5. Braslis KG, Santa-Cruz D, Brickman AL, and Soloway MS: Quality of life 12 months after radical prostatectomy. Br J Urol 75: 48-53, 1995.
6. Lim AJ, Brandon AH, Fiedler J, Brickman AL, Boyer CI, Raub WA Jr, and Soloway MS: Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol 154: 1433-1434, 1995.
7. Watkins-Bruner D, Scott C, Lawton C, DelRowe J, Rotman M, Buswell L, Beard C, and Cella D: RTOG's first quality of life study - RTOG 90-20: a Phase II trial of external beam radiation with etanidazole for locally advanced cancer. Int J Radiat Oncol Biol Phys 33: 901-906, 1995.
8. Herr HW, Kornblith AB, and Ofman U: A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 71: 1143-1150, 1993.
9. Frohmuller HG, Theiss M, Manseck A, and Wirth MP: Survival and quality of life of patients with state D1 (T1-3, pN1-2, M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone. Eur Urol 27: 202-206, 1995.
10. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Culla A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, and deHaes JC: The EORTC QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376, 1993.
11. Ware JE, and Sherbourne CD: The MOS 36-item short form health survey (SF-36): I. Conceptual framework and item selection. Med Care 30: 473-483, 1992.
12. McHorney CA, Ware JE, and Racjek A: The MOS 36 item short form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31: 247-263, 1993.
13. McHorney CA, Ware JE, Lu JF, and Sherbourne CD: The MOS 36 item short form health survey (SF-36): III. test of data quality, scaling assumptions and reliability across diverse patient groups. Med Care 32: 40-66, 1994.
14. Weeks J, O'Leary J, Fairclough D, Paltiel D, and Weinstein M: The "Q-Tility Index": a new tool for assessing health-related quality of life and utilities in clinical trials and clinical practice. American Society of Clinical Oncology, May 1994.
15. da Silva FC, Reis E, Costa T, and Denis L: Quality of life in patients with prostatic cancer. A feasibility study. The members of the quality of life committee of the EORTC genitourinary group. Cancer 71(suppl): 1138-1142, 1993.
16. Fossa SD, Aaronson NK, Newling D, van Cangh PJ, Denis L, Kurth KH, de Pauw M, and the members of the EORTC Genitourinary Group: Quality of life and treatment of hormone resistant metastatic prostatic cancer. Eur J Cancer 1: 1133-1136, 1990.
17. da Silva FC, Fossa SD, Aaronson NK, Serbouti S, Denis L, Casselman J, Whelan P, Hetherington J, Fava C, Richards B, and Robinson MR: The quality of life of patients with newly diagnosed Ml prostate cancer: experience with EORTC clinical trial 30853. Eur J Cancer 32A: 72-77, 1996.
18. Schag CA, Ganz PA, Wing DS, Sim MS, and Lee JJ: Quality of life in adult survivors of lung, colon and prostate cancer. Quality Life Res 3: 127-141, 1994.
19. Kornblith AB, Herr HW, Ofman US, Scher HI, and Holland JC: Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. Cancer 73: 2791-2802, 1994.
20. Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage B, Findlay B, Coppin C, Neville A, Venner P, and Wilson J: Use of palliative end points to evaluate the effects of mitox-antrone and low dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 12: 689-694, 1994.